Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
2.550
+0.230 (9.91%)
At close: Apr 23, 2025, 4:00 PM
2.700
+0.150 (5.88%)
Pre-market: Apr 24, 2025, 5:35 AM EDT
Regulus Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
168.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
RGLS News
- 21 days ago - Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - PRNewsWire
- 27 days ago - Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
- 4 weeks ago - Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 5 weeks ago - Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PRNewsWire
- 7 weeks ago - Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PRNewsWire
- 2 months ago - Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 3 months ago - Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - PRNewsWire
- 5 months ago - Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - PRNewsWire